The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Cytomegalovirus in Solid Organ Transplant Recipients
Open accessAbstract
CMV infection is a major cause of morbidity in patients receiving solid organ transplants. CMV is widely distributed in the general population with seroprevalence ranging from 30 to 97% (1-3). After primary infection, CMV establishes life-long latency. Without some form of prevention, CMV infection primarily occurs in the first 3 months following transplant. Onset may be delayed in patients receiving CMV prophylaxis. The following definitions are commonly used in the transplant literature and are consistent with the AST recommendations for use in clinical trials (4): CMV infection: evidence of CMV replication regardless of symptoms (differs from latent CMV). CMV disease: evidence of CMV infection with attributable symptoms. CMV disease can be further categorized as either a viral syndrome with fever and/or malaise, leukopenia, thrombocytopenia or as tissue invasive disease (e.g. pneumonitis, hepatitis, retinitis, gastrointestinal disease). In addition, several features unique to pediatric transplantation are discussed separately in this document. CMV has a predilection to invade the allograft, likely in part due to an aberrant immune response within the allograft (1). To directly attributable morbidity, CMV likely also has an immunomodulatory effect, and active CMV infection has been found to be an independent risk factor for the development of other infectious complications, such as bacteremia, invasive fungal disease and EBV-related PTLD (5, 6). CMV has also been implicated as a cause of acute and chronic allograft injury. There is evidence that CMV may play a crucial role in chronic graft vasculopathy resulting in lesions, such as chronic allograft nephropathy, bronchiolitis obliterans (lung transplant) and accelerated coronary artery disease (heart transplant) (5, 6). The risk of CMV disease is highest in donor-positive, recipient-seronegative (D+R–) solid organ transplant patients who lack cellular and humoral immunity to CMV. Other risk factors for disease include the recipient's overall state of immunosuppression determined by the immunosuppressive protocol (e.g. type of drug, dose, timing, duration) and various host factors (e.g. age, comorbidity, neutropenia). Antilymphocyte antibodies (ALA) (such as thymoglobulin) as either induction or antirejection therapy are associated with high rates of CMV disease (1-3). The risk is maximal when ALA therapy is used for the treatment of organ rejection, with CMV disease being diagnosed three to four times more frequently than in patients not receiving ALA therapy (2). The risk of CMV also varies with the type of transplant. Lung, small intestinal and pancreas transplant recipients have the highest risk for CMV while liver and kidney recipients are at lower risk for CMV disease. This may be due to the degree of immunosuppression, and/or the viral load present in the transplanted allograft. Co-infection with related viruses such as HHV-6 and 7 may also be an important risk factor for CMV disease (1). The lowest risk of CMV disease occurs in the D–/R– setting, provided these patients are given CMV negative blood or leukodepleted blood products (1). Pretransplant CMV IgG screening of donors and recipients should be performed to allow for risk stratification (II-1). CMV D–/R– transplant recipients should receive CMV negative blood or leukodepleted blood during and posttransplant (II-1). The diagnosis of CMV infection and disease has evolved considerably. Historically, the diagnosis of CMV disease has been made by histopathology. This approach is limited, however, by the fact that an invasive procedure is required to obtain samples. Serologic assays appear to have limited clinical utility posttransplant, and should not be used to diagnose acute disease in SOT patients (7). For years, culture-based methods (tissue culture and shell-vial centrifugation culture) were used for CMV diagnosis. Tissue culture can take weeks, however, and the shell-vial centrifugation assay is insensitive by comparison with molecular assays (8). Tissue culture methods may still useful in growing CMV isolates in the laboratory for phenotypic antiviral resistance testing, although the latter technique has been replaced predominantly by genotypic resistance testing. The pp65 antigenemia assay is a semi-quantitative fluorescent assay based on detection of infected cells in peripheral blood. This assay has far higher sensitivity and specificity than culture-based methods (8), and is comparable in sensitivity to CMV PCR (see further) (9). Though not fully quantitative, it can provide an estimate of the magnitude of viral load from the number of infected cells. Molecular diagnostic tests may detect DNA or RNA and can be qualitative and quantitative. The majority of these tests are quite sensitive for the detection of CMV. Measurement of quantitative CMV-DNA levels has become popular at many centres. Commonly used assays include plasma or whole blood based PCR testing which is either commercially
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paya, C., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., & Pescovitz, M. D. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00382.x · Cited by 880
Self-citationValacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Lowance, D., Neumayer, H.-H., Legendre, C. M., Squifflet, J.-P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401903 · Cited by 712
Emery, V. C., Sabin, C. A., Cope, A. V., Gor, D., Hassan-Walker, A. F., & Griffiths, P. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02350-3 · Cited by 545
Limaye, A. P., Corey, L., Koelle, D. M., Davis, C. L., & Boeckh, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02607-6 · Cited by 509
Gane, E., Saliba, F., Valdecasas, G. J., O'Grady, J., Pescovitz, M. D., Lyman, S., & Robinson, C. A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05535-9 · Cited by 496
Humar, A., & Michaels, M. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01207.x · Cited by 487
Self-citationAsberg, A., Humar, A., Rollag, H., Jardine, A. G., Mouas, H., Pescovitz, M. D., Sgarabotto, D., Tuncer, M., Noronha, I. L., & Hartmann, A. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01910.x · Cited by 430
Self-citationKalil, A. C., Levitsky, J., Lyden, E., Stoner, J., & Freifeld, A. G. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-12-200512200-00005 · Cited by 389
Cytomegalovirus in transplantation – challenging the status quo
Fishman, J. A., Emery, V., Freeman, R., Pascual, M., Rostaing, L., Schlitt, H. J., Sgarabotto, D., Torre‐Cisneros, J., & Uknis, M. E. (2007) · Clinical Transplantation · doi:10.1111/j.1399-0012.2006.00618.x · Cited by 289
Hibberd, P. L., Tolkoff-Rubin, N. E., Conti, D., Stuart, F., Thistlethwaite, J. R., Neylan, J. F., Snydman, D. R., Freeman, R., Lorber, M. I., & Rubin, R. H. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-1-199507010-00002 · Cited by 256
Self-citation
Cited by
Kotton, C. N., Kumar, D., Caliendo, A. M., Åsberg, A., Chou, S., Danziger-Isakov, L., & Humar, A. (2013) · Transplantation · doi:10.1097/tp.0b013e31829df29d · Cited by 758
Self-citationLucey, M. R., Terrault, N., Ojo, L., Hay, E. J., Neuberger, J., Blumberg, E., & Teperman, L. W. (2013) · Liver Transplantation · doi:10.1002/lt.23566 · Cited by 544
CMV: Prevention, Diagnosis and Therapy
Kotton, C. N. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12006 · Cited by 308
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
Hodson, E. M., Ladhani, M., Webster, A. C., Strippoli, G. F., & Craig, J. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003774.pub4 · Cited by 268
Baker, R. J., Mark, P. B., Patel, R. K., Stevens, K. K., & Palmer, N. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0553-2 · Cited by 211
Metadata
- Authors
- Humar, A., & Snydman, D.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 9
- Pages
- S78-S86
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1966858455
- Cited by
- 328
- References
- 25
- FWCI
- 18.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cytomegalovirus in Solid Organ Transplant Recipients. https://app.cochat.ai/papers/10.1111/j.1600-6143.2009.02897.x
- The paper
- Humar, A., & Snydman, D. (2009). Cytomegalovirus in Solid Organ Transplant Recipients. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2009.02897.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.